Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 154

1.

Myocyte-Damaging Effects and Binding Kinetics of Boronic Acid and Epoxyketone Proteasomal-Targeted Drugs.

Hasinoff BB, Patel D.

Cardiovasc Toxicol. 2018 Jun 27. doi: 10.1007/s12012-018-9468-9. [Epub ahead of print]

PMID:
29951728
2.

Progress curve analysis of the kinetics of slow-binding anticancer drug inhibitors of the 20S proteasome.

Hasinoff BB.

Arch Biochem Biophys. 2018 Feb 1;639:52-58. doi: 10.1016/j.abb.2017.12.020. Epub 2018 Jan 2.

PMID:
29305052
3.

Disulfiram is a slow-binding partial noncompetitive inhibitor of 20S proteasome activity.

Hasinoff BB, Patel D.

Arch Biochem Biophys. 2017 Nov 1;633:23-28. doi: 10.1016/j.abb.2017.09.003. Epub 2017 Sep 5.

PMID:
28887129
4.

The Myocyte-Damaging Effects of the BCR-ABL1-Targeted Tyrosine Kinase Inhibitors Increase with Potency and Decrease with Specificity.

Hasinoff BB, Patel D, Wu X.

Cardiovasc Toxicol. 2017 Jul;17(3):297-306. doi: 10.1007/s12012-016-9386-7.

PMID:
27696211
5.

Molecular Mechanisms of the Cardiotoxicity of the Proteasomal-Targeted Drugs Bortezomib and Carfilzomib.

Hasinoff BB, Patel D, Wu X.

Cardiovasc Toxicol. 2017 Jul;17(3):237-250. doi: 10.1007/s12012-016-9378-7.

PMID:
27388042
6.

Mechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase IIα Isoform.

Hasinoff BB, Wu X, Patel D, Kanagasabai R, Karmahapatra S, Yalowich JC.

J Pharmacol Exp Ther. 2016 Feb;356(2):397-409. doi: 10.1124/jpet.115.228650. Epub 2015 Dec 11.

7.

Structure-based design, synthesis and biological testing of piperazine-linked bis-epipodophyllotoxin etoposide analogs.

Yadav AA, Chee GL, Wu X, Patel D, Yalowich JC, Hasinoff BB.

Bioorg Med Chem. 2015 Jul 1;23(13):3542-51. doi: 10.1016/j.bmc.2015.04.022. Epub 2015 Apr 16.

8.

Cellular mechanisms of the cytotoxicity of the anticancer drug elesclomol and its complex with Cu(II).

Hasinoff BB, Wu X, Yadav AA, Patel D, Zhang H, Wang DS, Chen ZS, Yalowich JC.

Biochem Pharmacol. 2015 Feb 1;93(3):266-76. doi: 10.1016/j.bcp.2014.12.008. Epub 2014 Dec 27.

PMID:
25550273
9.

Structure-based design, synthesis and biological testing of etoposide analog epipodophyllotoxin-N-mustard hybrid compounds designed to covalently bind to topoisomerase II and DNA.

Yadav AA, Wu X, Patel D, Yalowich JC, Hasinoff BB.

Bioorg Med Chem. 2014 Nov 1;22(21):5935-49. doi: 10.1016/j.bmc.2014.09.014. Epub 2014 Sep 16.

10.

The cytotoxicity of the anticancer drug elesclomol is due to oxidative stress indirectly mediated through its complex with Cu(II).

Hasinoff BB, Yadav AA, Patel D, Wu X.

J Inorg Biochem. 2014 Aug;137:22-30. doi: 10.1016/j.jinorgbio.2014.04.004. Epub 2014 Apr 16.

PMID:
24798374
11.

Molecular mechanisms of the biological activity of the anticancer drug elesclomol and its complexes with Cu(II), Ni(II) and Pt(II).

Yadav AA, Patel D, Wu X, Hasinoff BB.

J Inorg Biochem. 2013 Sep;126:1-6. doi: 10.1016/j.jinorgbio.2013.04.013. Epub 2013 Apr 28.

PMID:
23707906
12.

The anticancer multi-kinase inhibitor dovitinib also targets topoisomerase I and topoisomerase II.

Hasinoff BB, Wu X, Nitiss JL, Kanagasabai R, Yalowich JC.

Biochem Pharmacol. 2012 Dec 15;84(12):1617-26. doi: 10.1016/j.bcp.2012.09.023. Epub 2012 Oct 5.

13.

The dual-targeted HER1/HER2 tyrosine kinase inhibitor lapatinib strongly potentiates the cardiac myocyte-damaging effects of doxorubicin.

Hasinoff BB, Patel D, Wu X.

Cardiovasc Toxicol. 2013 Mar;13(1):33-47. doi: 10.1007/s12012-012-9183-x.

PMID:
22948710
14.

The anticancer thiosemicarbazones Dp44mT and triapine lack inhibitory effects as catalytic inhibitors or poisons of DNA topoisomerase IIα.

Yalowich JC, Wu X, Zhang R, Kanagasabai R, Hornbaker M, Hasinoff BB.

Biochem Pharmacol. 2012 Jul 1;84(1):52-8. doi: 10.1016/j.bcp.2012.03.021. Epub 2012 Apr 4.

15.

Chemical reactivity and microbicidal action of bethoxazin.

Chee GL, Bhattarai B, Daniel Gietz R, Alrushaid S, Nitiss JL, Hasinoff BB.

Bioorg Med Chem. 2012 Feb 15;20(4):1494-501. doi: 10.1016/j.bmc.2011.12.051. Epub 2012 Jan 5.

PMID:
22264763
16.

Design, synthesis, and biological evaluation of a novel series of bisintercalating DNA-binding piperazine-linked bisanthrapyrazole compounds as anticancer agents.

Zhang R, Wu X, Yalowich JC, Hasinoff BB.

Bioorg Med Chem. 2011 Dec 1;19(23):7023-32. doi: 10.1016/j.bmc.2011.10.012. Epub 2011 Oct 14.

17.

A multifaceted evaluation of imatinib-induced cardiotoxicity in the rat.

Herman EH, Knapton A, Rosen E, Thompson K, Rosenzweig B, Estis J, Agee S, Lu QA, Todd JA, Lipshultz S, Hasinoff B, Zhang J.

Toxicol Pathol. 2011 Dec;39(7):1091-106. doi: 10.1177/0192623311419524. Epub 2011 Sep 21.

PMID:
21937741
18.

Cadmium is a catalytic inhibitor of DNA topoisomerase II.

Wu X, Yalowich JC, Hasinoff BB.

J Inorg Biochem. 2011 Jun;105(6):833-8. doi: 10.1016/j.jinorgbio.2011.02.007. Epub 2011 Feb 26.

19.

The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro.

Hasinoff BB, Patel D.

Toxicol Appl Pharmacol. 2010 Dec 1;249(2):132-9. doi: 10.1016/j.taap.2010.08.026. Epub 2010 Sep 9.

PMID:
20832415
20.

Design, synthesis and biological evaluation of a novel series of anthrapyrazoles linked with netropsin-like oligopyrrole carboxamides as anticancer agents.

Zhang R, Wu X, Guziec LJ, Guziec FS, Chee GL, Yalowich JC, Hasinoff BB.

Bioorg Med Chem. 2010 Jun 1;18(11):3974-84. doi: 10.1016/j.bmc.2010.04.028. Epub 2010 Apr 18.

21.

Kinamycin F downregulates cyclin D3 in human leukemia K562 cells.

O'Hara KA, Dmitrienko GI, Hasinoff BB.

Chem Biol Interact. 2010 Mar 30;184(3):396-402. doi: 10.1016/j.cbi.2010.01.013. Epub 2010 Jan 15.

PMID:
20079721
22.

The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity.

Hasinoff BB.

Toxicol Appl Pharmacol. 2010 Apr 15;244(2):190-5. doi: 10.1016/j.taap.2009.12.032. Epub 2010 Jan 4.

PMID:
20045709
23.

A diazirine-based photoaffinity etoposide probe for labeling topoisomerase II.

Chee GL, Yalowich JC, Bodner A, Wu X, Hasinoff BB.

Bioorg Med Chem. 2010 Jan 15;18(2):830-8. doi: 10.1016/j.bmc.2009.11.048. Epub 2009 Nov 27.

24.

Mechanisms of myocyte cytotoxicity induced by the multikinase inhibitor sorafenib.

Hasinoff BB, Patel D.

Cardiovasc Toxicol. 2010 Mar;10(1):1-8. doi: 10.1007/s12012-009-9056-0.

PMID:
19915982
25.

The iron chelator Dp44mT does not protect myocytes against doxorubicin.

Hasinoff BB, Patel D.

J Inorg Biochem. 2009 Jul;103(7):1093-101. doi: 10.1016/j.jinorgbio.2009.05.007. Epub 2009 May 21.

PMID:
19535146
26.

The structure-based design, synthesis, and biological evaluation of DNA-binding amide linked bisintercalating bisanthrapyrazole anticancer compounds.

Hasinoff BB, Zhang R, Wu X, Guziec LJ, Guziec FS Jr, Marshall K, Yalowich JC.

Bioorg Med Chem. 2009 Jul 1;17(13):4575-82. doi: 10.1016/j.bmc.2009.04.072. Epub 2009 May 6.

PMID:
19457675
27.

Development of a nitric oxide-releasing analogue of the muscle relaxant guaifenesin for skeletal muscle satellite cell myogenesis.

Wang G, Burczynski FJ, Hasinoff BB, Zhang K, Lu Q, Anderson JE.

Mol Pharm. 2009 May-Jun;6(3):895-904. doi: 10.1021/mp800226z.

PMID:
19317416
28.

Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.

Martin E, Thougaard AV, Grauslund M, Jensen PB, Bjorkling F, Hasinoff BB, Tjørnelund J, Sehested M, Jensen LH.

Toxicology. 2009 Jan 8;255(1-2):72-9. doi: 10.1016/j.tox.2008.10.011. Epub 2008 Oct 25.

PMID:
19010377
29.

The effect of the catalytic topoisomerase II inhibitor dexrazoxane (ICRF-187) on CC9C10 hybridoma viability and productivity.

Barnabé N, Butler M, Hasinoff BB.

Cytotechnology. 2001 Oct;37(2):107-17. doi: 10.1023/A:1019910213964.

30.

Mechanisms of myocyte cytotoxicity induced by the multiple receptor tyrosine kinase inhibitor sunitinib.

Hasinoff BB, Patel D, O'Hara KA.

Mol Pharmacol. 2008 Dec;74(6):1722-8. doi: 10.1124/mol.108.050104. Epub 2008 Sep 24.

31.

The dihydroorotase inhibitor 5-aminoorotic acid inhibits the metabolism in the rat of the cardioprotective drug dexrazoxane and its one-ring open metabolites.

Schroeder PE, Patel D, Hasinoff BB.

Drug Metab Dispos. 2008 Sep;36(9):1780-5. doi: 10.1124/dmd.108.021626. Epub 2008 May 30.

32.

Cell lysis with dimethyl sulphoxide produces stable homogeneous solutions in the dichlorofluorescein oxidative stress assay.

Wang G, Gong Y, Burczynski FJ, Hasinoff BB.

Free Radic Res. 2008 May;42(5):435-41. doi: 10.1080/10715760802074462.

PMID:
18484276
33.

The structure-based design, synthesis and biological evaluation of DNA-binding bisintercalating bisanthrapyrazole anticancer compounds.

Hasinoff BB, Liang H, Wu X, Guziec LJ, Guziec FS Jr, Marshall K, Yalowich JC.

Bioorg Med Chem. 2008 Apr 1;16(7):3959-68. doi: 10.1016/j.bmc.2008.01.033. Epub 2008 Jan 26.

34.

The use of dexrazoxane for the prevention of anthracycline extravasation injury.

Hasinoff BB.

Expert Opin Investig Drugs. 2008 Feb;17(2):217-23. doi: 10.1517/13543784.17.2.217. Review.

PMID:
18230055
35.

Thiol-modulated mechanisms of the cytotoxicity of thimerosal and inhibition of DNA topoisomerase II alpha.

Wu X, Liang H, O'Hara KA, Yalowich JC, Hasinoff BB.

Chem Res Toxicol. 2008 Feb;21(2):483-93. doi: 10.1021/tx700341n. Epub 2008 Jan 16.

PMID:
18197631
36.

A three-dimensional quantitative structure-activity analysis of a new class of bisphenol topoisomerase IIalpha inhibitors.

Liang H, Wu X, Yalowich JC, Hasinoff BB.

Mol Pharmacol. 2008 Mar;73(3):686-96. Epub 2007 Nov 28.

37.

Mechanism of the cytotoxicity of the diazoparaquinone antitumor antibiotic kinamycin F.

O'Hara KA, Wu X, Patel D, Liang H, Yalowich JC, Chen N, Goodfellow V, Adedayo O, Dmitrienko GI, Hasinoff BB.

Free Radic Biol Med. 2007 Oct 15;43(8):1132-44. Epub 2007 Jul 13.

38.

Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug?

Hasinoff BB, Herman EH.

Cardiovasc Toxicol. 2007;7(2):140-4. Review.

PMID:
17652819
39.

The cytotoxicity of celecoxib towards cardiac myocytes is cyclooxygenase-2 independent.

Hasinoff BB, Patel D, Wu X.

Cardiovasc Toxicol. 2007;7(1):19-27.

PMID:
17646679
40.

Total synthesis of isoprekinamycin: structural evidence for enhanced diazonium ion character and growth inhibitory activity toward cancer cells.

Liu W, Buck M, Chen N, Shang M, Taylor NJ, Asoud J, Wu X, Hasinoff BB, Dmitrienko GI.

Org Lett. 2007 Jul 19;9(15):2915-8. Epub 2007 Jun 22.

PMID:
17585773
41.

Evaluation of relative DNA binding affinities of anthrapyrazoles by electrospray ionization mass spectrometry.

Smith SI, Guziec LJ, Guziec FS Jr, Hasinoff BB, Brodbelt JS.

J Mass Spectrom. 2007 May;42(5):681-8.

PMID:
17405184
42.

Role of NADPH cytochrome P450 reductase in activation of RH1.

Begleiter A, Leith MK, Patel D, Hasinoff BB.

Cancer Chemother Pharmacol. 2007 Oct;60(5):713-23. Epub 2007 Jan 26.

PMID:
17256129
44.

Kinamycins A and C, bacterial metabolites that contain an unusual diazo group, as potential new anticancer agents: antiproliferative and cell cycle effects.

Hasinoff BB, Wu X, Yalowich JC, Goodfellow V, Laufer RS, Adedayo O, Dmitrienko GI.

Anticancer Drugs. 2006 Aug;17(7):825-37.

PMID:
16926632
45.
46.

A structure-based 3D-QSAR study of anthrapyrazole analogues of the anticancer agents losoxantrone and piroxantrone.

Liang H, Wu X, Guziec LJ, Guziec FS Jr, Larson KK, Lang J, Yalowich JC, Hasinoff BB.

J Chem Inf Model. 2006 Jul-Aug;46(4):1827-35.

PMID:
16859314
47.

Structure-activity studies with cytotoxic anthrapyrazoles.

Begleiter A, Lin D, Larson KK, Lang J, Wu X, Cabral T, Taylor H, Guziec LJ, Kerr PD, Hasinoff BB, Guziec FS Jr.

Oncol Rep. 2006 Jun;15(6):1575-80.

PMID:
16685398
48.

Dexrazoxane use in the prevention of anthracycline extravasation injury.

Hasinoff BB.

Future Oncol. 2006 Feb;2(1):15-20. Review.

PMID:
16556068
49.

Structure-activity study of the interaction of bioreductive benzoquinone alkylating agents with DNA topoisomerase II.

Hasinoff BB, Wu X, Begleiter A, Guziec LJ, Guziec F Jr, Giorgianni A, Yang S, Jiang Y, Yalowich JC.

Cancer Chemother Pharmacol. 2006 Jan;57(2):221-33. Epub 2005 Jul 12.

PMID:
16010589
50.

Supplemental Content

Loading ...
Support Center